About
Tay Salimullah is the Founder and Managing General Partner at Renovamen Advisors LLC, where he works with founders, boards, and investors on company building, commercialization, governance, and investment for early-stage biotechs. Previously a member of the Novartis Gene Therapies executive team, he contributed to the development of Zolgensma into a global gene therapy franchise approved in more than 50 countries. He also serves as Venture Partner at 4BIO Capital, Chief Strategy Officer and Board Member at Trogenix, Board Advisor to iECURE, and Executive-in-Residence at the Alliance for Regenerative Medicine.
Experience
- Renovamen Advisors LLCFounder, Managing General Partnercurrent2024 — presentChicago, Illinois, United States
- TrogenixBoard Member & Chief Strategy Officercurrent2024 — present
- iECURE, inc.Board Commercial Advisorcurrent2025 — present
- 4BIO CapitalVenture Partnercurrent2024 — presentChicago, USA, London
- Alliance for Regenerative MedicineExecutive in Residencecurrent2024 — present
- Novartis Gene TherapiesCCO (formerly AveXis)2020 — 2024Greater Chicago Area
- Novartis Global HealthHead Global Business Franchise, Group Global Health2018 — 2020Basel Area, Switzerland
- NovartisGlobal Strategic Projects Leader, Worldwide Real World Evidence2017 — 2018Basel Area, Switzerland
- NovartisEx.Director US & Global Pricing & Market Access Cell & Gene Therapies2015 — 2017Basel Area, Switzerland
- Novartis OncologyGlobal Head Hematology RWE Program2015 — 2017Basel Area, Switzerland
- NovartisRegion Europe Market Access & Pricing Director2013 — 2015Basel Area, Switzerland
- Ascendancy HealthcareMarket Access Consultant - Singapore2012 — 2013Singapore
- Clermont GroupAssistant Vice President - Singapore2011 — 2012Singapore
- PfizerHealthcare Strategy Lead - Oncology Franchise2009 — 2011United Kingdom
- PfizerHead Strategic Market Access Payors2008 — 2009Europe
- PfizerPayor Strategy Leader - Strategic Market Access2007 — 2008London Area, United Kingdom
- PfizerCommercial Director - Oncology Franchise2005 — 2007United Kingdom
- PfizerHospital Sales Manager2002 — 2005London Area, United Kingdom
- USAIDStrategic Planning Consultant - AFRICA2009Malawi
- PfizerPrimary Care Sales Executive2000 — 2001London, United Kingdom
Skills & more
Market Access45Pharmaceutical Industry37Oncology29Business Strategy13Strategy7International Development4Big Data1Leadership8Cross-functional Team Leadership4Cell & Gene Therapies1
Languages English · Hindi · Punjabi · Urdu
- Venture Capital and Private Equity: Investment Strategies — Imperial College London
- Venture Capital and Private Equity: Investment Strategies — Imperial Business School
- Venture Capital and Private Equity: Investment Strategies — Imperial Business School
From Tay's professional profile.
Colleagues at 4BIO Capital
Alexander Mckenna
Investment Associate at 4BIO Capital
Andrew Kozlov
Managing Partner at 4BIO Capital
Brian McVeigh
Venture Partner, USA at 4BIO Capital
Dima Kuzmin
Managing Partner at 4BIO Capital
Edward McGill
Financial Controller at 4BIO Capital
Eleanor Whate
Office Manager and Compliance Assistant at 4BIO Capital
Jack Shea-Firth
Investment Analyst at 4BIO Capital
Kieran Mudryy
Partner at 4BIO Capital
Frequently asked questions
- Who is Tay Salimullah?
- Tay Salimullah is the Founder and Managing General Partner at Renovamen Advisors LLC, where he works with founders, boards, and investors on company building, commercialization, governance, and investment for early-stage biotechs. Previously a member of the Novartis Gene Therapies executive team, he contributed to the development of Zolgensma into a global gene therapy franchise approved in more than 50 countries. He also serves as Venture Partner at 4BIO Capital, Chief Strategy Officer and Board Member at Trogenix, Board Advisor to iECURE, and Executive-in-Residence at the Alliance for Regenerative Medicine.
- Where does Tay Salimullah work?
- Tay Salimullah is Venture Partner at 4BIO Capital.
- Where did Tay Salimullah go to school?
- Tay Salimullah studied at Imperial College London (Executive Education, Venture Capital and Private Equity); Boston University School of Public Health (Pfizer Global Health Fellowship (Class 10), International Public Health); Brunel University of London (BSc Business Management Studies).
Same school
Also attended Imperial College London499
Deji SasegbonVP, Platform & Portfolio Operations at EchoVC PartnersMadison LenormandInvestor at DaphniPauline BoucherInvestor at DaphniLoubaba El AyoubiInvestor at NorthzoneGiovanni MariggiInvestor at MedicxiFrancois PrinslooInvestor at Medicxi
+ 493 more
Also attended Boston University School of Public Health4
Also attended Brunel University of London29
Paul BazinInvestor at DaphniSimon MurdochGeneral Partner, PhD at Episode1Hamdullah MohibCEO, Marlan Space at Cortado VenturesSurjit KoonerManaging Director, Regional at Future Planet CapitalAli QaiserMENA at Salica InvestmentsOlly BettsSector Director, Fintech at Founders Factory
+ 23 more
Shared employers
Also worked at Trogenix3
Also worked at 4BIO Capital13
Vasily FedorinChief Operating Officer at 4BIO CapitalNatalie JohnstonInvestment Principal at 4BIO CapitalAndrew KozlovManaging Partner at 4BIO CapitalDima KuzminManaging Partner at 4BIO CapitalTherese LiechtensteinPartner at 4BIO CapitalAlexander MckennaInvestment Associate at 4BIO Capital
+ 7 more
Also worked at Novartis Gene Therapies130
Rebecca JamesInvestor at Index VenturesScott BillerInvestor at GV (Google Ventures)Freya Svedberg-KeatingInvestor at MedicxiAndrea AmadorCompliance Manager at Inveready Technology Investment GroupAbbie CelnikerInvestor at Third Rock VenturesJesper GromadaInvestor at Third Rock Ventures
+ 124 more
Also worked at Pfizer152
Jigar RaythathaInvestor at Third Rock VenturesAbbie CelnikerInvestor at Third Rock VenturesErin MooreInvestor at Third Rock VenturesJeb KeiperInvestor at Third Rock VenturesRichard ChesworthInvestor at Third Rock VenturesBriggs MorrisonEntrepreneur Partner at MPM BioImpact
+ 146 more